Keryx names new COO
This article was originally published in Scrip
Executive Summary
New York-based Keryx Biopharmaceuticals, which develops products for the treatment of renal disease, has named Greg Madison executive vice-president and chief operating officer – effective from 10 February. Mr Madison joins the company from AMAG Pharmaceuticals where he was executive vice-president and chief commercial officer.